[Effect of lymph-stimulating drugs on the clinical manifestations and parameters of lipid metabolism in patients with post-infarction cardiosclerosis and angina pectoris].

As many as 64 patients with coronary heart disease (CHD) were examined. They were divided into 3 groups: (1) control subjects; (2) patients on supplementary rheogluman and (3) those on supplementary haemodesum (neocompensan). Their status was assessed from the frequency and intensity of anginal attacks, the magnitude of changes in lipid metabolic parameters prior to and following the therapy.